Adding folate to the contraceptive pill: A new concept for the prevention of neural tube defects

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 25, Issue 9, 2012, Pages 1529-1536

  Holzgreve, Wolfgang ^a   Pietrzik, Klaus ^b   Koletzko, Berthold ^c   Eckmann Scholz, Christel ^d  

^a Institute of Advanced Research   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Folate application; Neural tube defects; Oral contraceptives

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; ELEVIT PRONATAL; FOLIC ACID; MULTIVITAMIN; ORAL CONTRACEPTIVE AGENT; PLACEBO; UNCLASSIFIED DRUG;

ANENCEPHALUS; CHEMOPROPHYLAXIS; CHROMOSOME ABERRATION; COMBINATION CHEMOTHERAPY; DIET SUPPLEMENTATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; ECONOMIC ASPECT; ENCEPHALOCELE; GENETIC PREDISPOSITION; HUMAN; MONOTHERAPY; NEURAL TUBE DEFECT; PATIENT COMPLIANCE; PERINATAL CARE; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; REVIEW; SPINA BIFIDA; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION;

ADMINISTRATION, ORAL; CONCEPT FORMATION; CONTRACEPTIVE AGENTS; DRUG COMBINATIONS; FEMALE; FOLIC ACID; HUMANS; INFANT, NEWBORN; NEURAL TUBE DEFECTS; PREGNANCY; TABLETS;

EID: 84865478639     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767058.2011.648672     Document Type: Review

References (56)

1. Sohn CH, Tercanli S, Holzgreve W. Ultraschall in Gynäkologie und Geburtshilfe. Heidelberg: Springer; 2003.
2. Available at: www.who.int/en/
3. Czeizel AE. Specified critical period of different congenital abnormalities: a new approach for human teratological studies. Congenit Anom (Kyoto) 2008;48:103-109.
4. Warkany J. Congenital malformations. Notes and comments. Chicago, IL: Year Book Medical Publishers; 1971.
5. Field B. Anencephalus, encephalocele and spinal meningomyelocele. Med J Aust 1974;1:889-890.
6. Bower C, D'Antoine H, Stanley FJ. Neural tube defects in Australia: trends in encephaloceles and other neural tube defects before and after promotion of folic acid supplementation and voluntary food fortification. Birth Defects Res Part A Clin Mol Teratol 2009;85:269-273.
7. Czeizel AE. Schisis association. Am J Med Genet 1981;10:25-35.
8. Czeizel AE, Medveczky E. Periconceptional multivitamin supplementation and multimalformed offspring. Obstet Gynecol 2003; 102:1255-1261. (Pubitemid 37518404)
9. Czeizel AE, Puhó EH, Bánhidy F. No association between periconceptional multivitamin supplementation and risk of multiple congenital abnormalities: a population-based case-control study. Am J Med Genet A 2006;140:2469-2477. (Pubitemid 44684943)
10. Stevenson AC, Johnston HA, Stewart MI, Golding DR. Congenital malformations. A report of a study of series of consecutive births in 24 centres. Bull World Health Organ 1966;34 Suppl:9-127.
11. Ren A, Zhang L, Li Z, Hao L, Tian Y, Li Z. Awareness and use of folic acid, and blood folate concentrations among pregnant women in northern China-an area with a high prevalence of neural tube defects. Reprod Toxicol 2006;22:431-436. (Pubitemid 44344446)
12. Czeizel A, Révész C. Major malformations of the central nervous system in Hungary. Br J Prev Soc Med 1970;24:205-222.
13. Czeizel A, Sankaranarayanan K. The load of genetic and partially genetic disorders in man. I. Congenital anomalies: estimates of detriment in terms of years of life lost and years of impaired life. Mutat Res 1984;128:73-103. (Pubitemid 14052379)
14. Bentley TG, Weinstein MC, Willett WC, Kuntz KM. A cost-effectiveness analysis of folic acid fortification policy in the United States. Public Health Nutr 2009;12:455-467.
15. Pietrzik K, Bailey L, Shane B. Folic acid and l-5-methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2010;49:535-548.
16. Perry J, Chanarin I. Intestinal absorption of reduced folate compounds in man. Br J Haematol 1970;18:329-339.
17. Fohr IP, Prinz-Langenohl R, Brönstrup A, Bohlmann AM, Nau H, Berthold HK, Pietrzik K. 5,10-Methylenetetrahydrofolate reductase genotype determines the plasma homocysteine-lowering effect of supplementation with 5-methyltetrahydrofolate or folic acid in healthy young women. Am J Clin Nutr 2002;75:275-282. (Pubitemid 34101212)
18. Smithells RW, Sheppard S, Schorah CJ. Vitamin dificiencies and neural tube defects. Arch Dis Child 1976;51:944-950. (Pubitemid 8021028)
19. Smithells RW, Sheppard S, Schorah CJ, Seller MJ, Nevin NC, Harris R, Read AP, Fielding DW. Possible prevention of neural-tube defects by periconceptional vitamin supplementation. Lancet 1980;1:339-340. (Pubitemid 10219521)
20. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991;338:131-137.
21. Czeizel AE. Reduction of urinary tract and cardiovascular defects by periconceptional multivitamin supplementation. Am J Med Genet 1996;62:179-183.
22. Laurence KM, James N, Miller MH, Tennant GB, Campbell H. Doubleblind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. Br Med J (Clin Res Ed) 1981;282:1509-1511. (Pubitemid 11096562)
23. Mulinare J, Cordero JF, Erickson JD, Berry RJ. Periconceptional use of multivitamins and the occurrence of neural tube defects. JAMA 1988;260:3141-3145.
24. Bower C, Stanley FJ. Dietary folate as a risk factor for neural-tube defects: evidence from a case-control study in Western Australia. Med J Aust 1989;150:613-619. (Pubitemid 19193772)
25. Simpson JL, Mills JL, Rhoads GG, Cunningham GC, Hoffman HJ, Conley MR. Vitamins, folic acid and neural tube defects: comments on investigations in the United States. Prenat Diagn 1991; 11:641-648.
26. Milunsky A, Jick H, Jick SS, Bruell CL, MacLaughlin DS, Rothman KJ, Willett W. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. JAMA 1989;262:2847-2852. (Pubitemid 20002544)
27. Vergel RG, Sanchez LR, Heredero BL, Rodriguez PL, Martinez AJ. Primary prevention of neural tube defects with folic acid supplementation: Cuban experience. Prenat Diagn 1990;10:149-152. (Pubitemid 20184778)
28. Czeizel AE, Dudás I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992;327:1832-1835. (Pubitemid 23003073)
29. Shaw GM, Schaffer D, Velie EM, Morland K, Harris JA. Periconceptional vitamin use, dietary folate, and the occurrence of neural tube defects. Epidemiology 1995;6:219-226.
30. Berry RJ, Li Z, Erickson JD, Li S, Moore CA, Wang H, Mulinare J, et al. Prevention of neural-tube defects with folic acid in China. China-U.S. Collaborative Project for Neural Tube Defect Prevention. N Engl J Med 1999;341:1485-1490. (Pubitemid 29526350)
31. Goh YI, Bollano E, Einarson TR, Koren G. Prenatal multivitamin supplementation and rates of congenital anomalies: a meta-analysis. J Obstet Gynaecol Can 2006;28:680-689.
32. Daly LE, Kirke PN, Molloy A, Weir DG, Scott JM. Folate levels and neural tube defects. Implications for prevention. JAMA 1995;274:1698-1702.
33. Daly S, Mills JL, Molloy AM, Conley M, Lee YJ, Kirke PN, Weir DG, Scott JM. Minimum effective dose of folic acid for food fortification to prevent neural-tube defects. Lancet 1997;350:1666-1669. (Pubitemid 28036827)
34. Busby A, Abramsky L, Dolk H, Armstrong B, Addor MC, Anneren G, Armstrong N, et al. Preventing neural tube defects in Europe: a missed opportunity. Reprod Toxicol 2005;20:393-402. (Pubitemid 40943559)
35. Spina bifida and anencephaly before and after folic acid mandate-United States, 1995-1996 and 1999-2000. MMWR Morb Mortal Wkly Rep 2004;53:362-365.
36. EUROCAT Special Report. (May 2003). Available at: http://www. eurocat.ulster.ac.uk/pdf/Part%20I.pdf
37. Achterbergh R, Lakeman P, Stemerding D, Moors EH, Cornel MC. Implementation of preconceptional carrier screening for cystic fibrosis and haemoglobinopathies: a sociotechnical analysis. Health Policy 2007;83:277-286. (Pubitemid 47259215)
38. de Jong-van den Berg LTW, van der Zee AH, Schaafsma E, et al. Counselling women about periconceptional use of folic acid: the role of the community pharmacist can be improved. Int J Pharmaceut Pract 1999;7:138-142. (Pubitemid 29511788)
39. Meijer WM, de Smit DJ, Jurgens RA, de Jong-van den Berg LTW. Improved periconceptional use of folic acid after patient education in pharmacies: promising results of a pilot study in the Netherlands. Int J Pharmaceut Pract 2005;13:47-51. (Pubitemid 40314146)
40. de Walle HE, de Jong-van den Berg LT. Ten years after the Dutch public health campaign on folic acid: the continuing challenge. Eur J Clin Pharmacol 2008;64:539-543.
41. Cornel MC, de Smit DJ, de Jong-van den Berg LT. Folic acid-the scientific debate as a base for public health policy. Reprod Toxicol 2005;20:411-415. (Pubitemid 40943561)
42. Health Council of the Netherlands. Towards an optimal use of folic acid. Publication no. 2008/02E. The Hague: Health Council of the Netherlands, 2008. Available at: http://www.gezondheidsraad.nl/sites/default/files/200802E/0.pdf. Accessed on 28 May 2010.
43. Dinger JC, Heinemann LAJ, Westhoff C, Cronin M, Schellschmidt. Contraceptive efficacy of oral contraceptives in real world clinical practice: The impact of age, weight, BMI, dose, and duration of use. ACOG 2007, Poster Presentation.
44. IMS MIDAS, Worldbank Population 2010 EU29.
45. Bakker DJ, de Jong-van den Berg LT, Fokkema MR. Controlled study on folate status following folic acid supplementation and discontinuation in women of child-bearing age. Ann Clin Biochem 2009;46:231-234.
46. van Eijsden M, Smits LJ, van der Wal MF, Bonsel GJ. Association between short interpregnancy intervals and term birth weight: the role of folate depletion. Am J Clin Nutr 2008;88:147-153. (Pubitemid 351988694)
47. Barnhart KT, Schreiber CA. Return to fertility following discontinuation of oral contraceptives. Fertil Steril 2009;91:659-663.
48. Cronin M, Schellschmidt I, Dinger J. Rate of pregnancy after using drospirenone and other progestin-containing oral contraceptives. Obstet Gynecol 2009;114:616-622.
49. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-497. (Pubitemid 41127293)
50. Oakley D, Sereika S, Bogue EL. Oral contraceptive pill use after an initial visit to a family planning clinic. Fam Plann Perspect 1991; 23:150-154.
51. Smith JD, Oakley D. Why do women miss oral contraceptive pills? An analysis of women's self-described reasons for missed pills. J Midwifery Womens Health 2005;50:380-385. (Pubitemid 41264363)
52. Center for Disease Control and Prevention. Use of dietary supplements containing folic acid among women of childbearing age ? United States, 2005. MMWR Morb Mortal Wkly Rep 2005;54:955-8. Available at: http://www.cdc.gov/mmwr/ preview/mmwrhtml/mm5438a4.htm. Accessed on 28 February 2010.
53. Inskip HM, Crozier SR, Godfrey KM, Borland SE, Cooper C, Robinson SM; Southampton Women's Survey Study Group. Women's compliance with nutrition and lifestyle recommendations before pregnancy: general population cohort study. BMJ 2009;338:b481.
54. Pashley S, O'Donoghue MF. The safety of anti-epileptic drug regimens: a qualitative study of factors determining the success of counselling women before conception. J Fam Plann Reprod Health Care 2009;35:153-156.
55. Osterhues A, Holzgreve W, Michels KB. Shall we put the world on folate? Lancet 2009;374:959-961.
56. US Food and Drug Administration, Center for Drug Evaluation and Research. Advisory Committee for Reproductive Health drugs meeting. Summary minutes, 15 December 2003. Available at: http://www.fda. gov/ohrms/dockets/ac/03/minutes/ 4002M1/Final.htm. Accessed on 28 February 2010.